$8.47
1.97% yesterday
Nasdaq, Jun 30, 10:02 pm CET
ISIN
CA05156V1022
Symbol
AUPH
Sector
Industry

Aurinia Pharmaceuticals Inc. Stock price

$8.47
+0.63 8.04% 1M
-0.70 7.63% 6M
-0.51 5.68% YTD
+2.98 54.28% 1Y
-1.58 15.72% 3Y
-7.78 47.88% 5Y
+5.45 180.46% 10Y
-82.78 90.72% 20Y
Nasdaq, Closing price Mon, Jun 30 2025
-0.17 1.97%
ISIN
CA05156V1022
Symbol
AUPH
Sector
Industry

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$903.1m
Net debt
positive
Cash
$312.6m
Shares outstanding
137.8m
Valuation (TTM | estimate)
P/E
30.25 | 14.17
P/S
4.63 | 4.34
EV/Sales
3.65 | 3.42
EV/FCF
14.11
P/B
3.33
Financial Health
Equity Ratio
68.55%
Return on Equity
1.52%
ROCE
11.08%
ROIC
25.36%
Debt/Equity
0.20
Financials (TTM | estimate)
Revenue
$247.3m | $263.7m
EBITDA
$67.8m | $99.8m
EBIT
$48.4m
Net Income
$39.9m | $82.3m
Free Cash Flow
$64.0m
Growth (TTM | estimate)
Revenue
29.20% | 12.15%
EBITDA
228.45% | 163.57%
EBIT
170.43%
Net Income
163.70% | 1,332.00%
Free Cash Flow
410.53%
Margin (TTM | estimate)
Gross
88.24%
EBITDA
27.43% | 37.84%
EBIT
19.56%
Net
16.11% | 31.22%
Free Cash Flow
25.88%
More
EPS
$0.28
FCF per Share
$0.46
Short interest
8.52%
Employees
130.00
Rev per Employee
$1.81m
Show more

Is Aurinia Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

Aurinia Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

Buy
83%
Hold
17%

Financial data from Aurinia Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
247 247
29% 29%
100%
- Direct Costs 29 29
35% 35%
12%
218 218
28% 28%
88%
- Selling and Administrative Expenses 145 145
25% 25%
58%
- Research and Development Expense 21 21
50% 50%
8%
68 68
228% 228%
27%
- Depreciation and Amortization 19 19
23% 23%
8%
EBIT (Operating Income) EBIT 48 48
170% 170%
20%
Net Profit 40 40
164% 164%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Aurinia Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aurinia Pharmaceuticals Inc. Stock News

Neutral
Business Wire
about 19 hours ago
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200).
Neutral
Business Wire
one day ago
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025.
Positive
Proactive Investors
4 days ago
Shares of Aurinia Pharmaceuticals (TSX:AUP)(NASDAQ:AUPH) jumped 6.8% to $8.57 on Thursday afternoon as investors looked ahead to the company's first clinical data update for its experimental autoimmune drug AUR200, which Jefferies said could carry significant strategic value. Jefferies upgraded its outlook on the BAFF/APRIL dual inhibitor, noting the upcoming results from a single ascending dos...
More Aurinia Pharmaceuticals Inc. News

Company Profile

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Head office Canada
CEO Peter Greenleaf
Employees 130
Founded 1993
Website www.auriniapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today